| Maureen Cassin, MD | |
|
1235 Old York Rd, Suite 220, Abington, PA 19001-3800 | |
| (215) 481-6350 | |
| (215) 481-6359 |
| Full Name | Maureen Cassin |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Infectious Disease |
| Location | 1235 Old York Rd, Abington, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891741625 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | MD422802 (Pennsylvania) | Primary |
| Entity Name | Amh Medical Staff Service Fund |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356384457 PECOS PAC ID: 9830003813 Enrollment ID: O20031114000011 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and Aurigene Discovery Technologies Ltd., a Bangalore based fully integrated, global biotech focused on small molecule and peptide drug discovery and development from target identification and validation to pre IND drug candidates, today announced the successful nomination of a development candidate, Debio 0617, a novel inhibitor of an undisclosed oncology pathway.
There is a significant need for objective tests that could improve clinical prediction of future psychosis. One strategy has been to determine whether physiologic measures that are abnormal in people diagnosed with schizophrenia might also be useful in estimating the risk for developing this illness. This is the strategy taken by German and Swiss researchers in the current issue of Biological Psychiatry.
The Canadian Association of Radiologists (CAR) recently contributed to a report produced by the Health Council of Canada (HCC) entitled "Decisions, Decisions: Family Doctors as Gatekeepers in the Use of Prescription Drugs and Diagnostic Imaging in Canada." This report, which was released today, supports one of the CAR's main objectives: to implement medical imaging guidelines at a national level to guide physicians in selecting the most effective diagnostic imaging exam the first time.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ"), has received regulatory approval from Brazil's National Health Surveillance Agency (Anvisa) to market Chembio's Dual Path Platform (DPP®) HIV 1/2 rapid test for use with oral fluid, blood, serum or plasma samples. The approval triggers $400,000 in license revenues payable to Chembio within 120 days of the date of approval.
› Verified 4 days ago
| Entity Name | Abington Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962554576 PECOS PAC ID: 3274437736 Enrollment ID: O20060223000079 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and Aurigene Discovery Technologies Ltd., a Bangalore based fully integrated, global biotech focused on small molecule and peptide drug discovery and development from target identification and validation to pre IND drug candidates, today announced the successful nomination of a development candidate, Debio 0617, a novel inhibitor of an undisclosed oncology pathway.
There is a significant need for objective tests that could improve clinical prediction of future psychosis. One strategy has been to determine whether physiologic measures that are abnormal in people diagnosed with schizophrenia might also be useful in estimating the risk for developing this illness. This is the strategy taken by German and Swiss researchers in the current issue of Biological Psychiatry.
The Canadian Association of Radiologists (CAR) recently contributed to a report produced by the Health Council of Canada (HCC) entitled "Decisions, Decisions: Family Doctors as Gatekeepers in the Use of Prescription Drugs and Diagnostic Imaging in Canada." This report, which was released today, supports one of the CAR's main objectives: to implement medical imaging guidelines at a national level to guide physicians in selecting the most effective diagnostic imaging exam the first time.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ"), has received regulatory approval from Brazil's National Health Surveillance Agency (Anvisa) to market Chembio's Dual Path Platform (DPP®) HIV 1/2 rapid test for use with oral fluid, blood, serum or plasma samples. The approval triggers $400,000 in license revenues payable to Chembio within 120 days of the date of approval.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Maureen Cassin, MD 1235 Old York Rd, Suite 220, Abington, PA 19001-3800 Ph: (215) 481-6350 | Maureen Cassin, MD 1235 Old York Rd, Suite 220, Abington, PA 19001-3800 Ph: (215) 481-6350 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and Aurigene Discovery Technologies Ltd., a Bangalore based fully integrated, global biotech focused on small molecule and peptide drug discovery and development from target identification and validation to pre IND drug candidates, today announced the successful nomination of a development candidate, Debio 0617, a novel inhibitor of an undisclosed oncology pathway.
There is a significant need for objective tests that could improve clinical prediction of future psychosis. One strategy has been to determine whether physiologic measures that are abnormal in people diagnosed with schizophrenia might also be useful in estimating the risk for developing this illness. This is the strategy taken by German and Swiss researchers in the current issue of Biological Psychiatry.
The Canadian Association of Radiologists (CAR) recently contributed to a report produced by the Health Council of Canada (HCC) entitled "Decisions, Decisions: Family Doctors as Gatekeepers in the Use of Prescription Drugs and Diagnostic Imaging in Canada." This report, which was released today, supports one of the CAR's main objectives: to implement medical imaging guidelines at a national level to guide physicians in selecting the most effective diagnostic imaging exam the first time.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ"), has received regulatory approval from Brazil's National Health Surveillance Agency (Anvisa) to market Chembio's Dual Path Platform (DPP®) HIV 1/2 rapid test for use with oral fluid, blood, serum or plasma samples. The approval triggers $400,000 in license revenues payable to Chembio within 120 days of the date of approval.
› Verified 4 days ago
Dr. Shaili Nepal, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2191 Fax: 215-481-3411 | |
Muhammad Arslan Asghar Cheema, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2222 Fax: 215-481-4361 | |
Margaret Mack, Infectious Disease Medicare: Medicare Enrolled Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2000 | |
Joseph Guererri Crocetti Jr., DO Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1235 Old York Rd, Ste 121, Abington, PA 19001 Phone: 215-517-1200 Fax: 215-517-1219 | |
Dr. Joseph Mcallister, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1235 Old York Rd, Ste 113, Abington, PA 19001 Phone: 215-517-1180 | |
William L. Ward, DO Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1235 Old York Rd, Suite 121, Abington, PA 19001 Phone: 215-517-1200 Fax: 215-517-1219 | |
Rebecca Jane Fallis, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1235 Old York Rd Ste 220, Abington, PA 19001 Phone: 215-481-6350 Fax: 215-481-4237 |